Board of Directors

Jan Provis is Emeritas Professor at the Australian National University where she was Associate Dean (Research) in the ANU Medical School, and led a team investigating development and aging of the macula, including studies focussed on age-related macular degeneration. Jan has a distinguished track record in visual neuroscience, authoring more than 100 scientific papers which have attracted around 5000 citations in the scientific literature. This body of work provides a broad perspective on how the macular / foveal part of the primate retina has evolved, how it develops, the molecular factors involved, the functional constraints, and why the macula is vulnerable to degeneration. Her research team at the ANU pioneered the rodent light-induced model of photo-oxidative retinal damage, which is proving to be a very useful model for investigating therapeutic approaches for the management of dry AMD. She has a track record in leadership, mentoring of early career scientists and research consultancy.

Editor/Author of the textbook: “Macular Degeneration”. Held senior academic positions at Sydney University and at Australian National University and is currently an adjunct professor at ANU’s John Curtin School of Medical Research. Led the scientific team at Regenera Ltd/Advanced Ocular Systems from start up, to oversubscribed IPO on the ASX, on to transactions with Alcon, QLT and others. His initial inventions including the triamcinolone ocular injection method, were licensed by Alcon in a high value transaction in 2005, and products he developed are now on global markets with regulatory approvals, including from USFDA.

Senior executive with more than 30 years’ experience as CEO, and Managing Director of an ASX listed company and of major subsidiaries of the ophthalmic companies Allergan and Advanced Medical Optics. Operated in Australia, New Zealand and in several Asian markets based in Hong Kong and Shanghai. Director of the Macular Disease Foundation of Australia. Proven skills in the pharmaceutical, medical device, FMCG and OTC sectors with demonstrated effectiveness in leadership, strategic  planning, and transformational change.

Consultant to ASX listed business, Memphasys Ltd,  and for 10 years, until Dec 2023, Managing Director/Executive Chairman. Memphasys (ASX: MEM) is a medtech company focussed on developing innovative reproductive medicine products. Co-founder of financial services, medtech and biotech companies including eG Capital, a preeminent financial advisory firm in the Australian Life Sciences sector, Micro-X (ASX: MX1), a carbon nano technology company developing and now selling portable and miniaturised X-Ray devices internationally,  and Mariposa Health, a lung function drug development company planning to list on the ASX shortly.

Brings extensive experience and networks across several industry sectors and disciplines including investment banking with eG Capital, technology commercialisation (Memphasys, Micro-X and Mariposa Health) as well as international engineering project management with Bechtel Corporation, strategy consulting with Boston Consulting Group, and executive search with Egon Zehnder International. Formerly Chair of CSIRO’s Health Sector Advisory

RO’s Health Sector Advisory Council and co-founder and director of eG Capital, a preeminent financial advisory firm in the Australian Life Sciences sector.